Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype

Oncotarget

Volumn 6, Issue 7, 2015, Pages 5324-5341

  Milone, Maria Rita ^a   Pucci, Biagio ^a   Bifulco, Katia ^a   Iannelli, Federica ^a   Lombardi, Rita ^a   Ciardiello, Chiara ^a   Bruzzese, Francesca ^a   Carriero, Maria Vincenza ^a   Budillon, Alfredo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Av integrin; Cytoskeleton organization; Prostate cancer; Urokinase receptor (uPAR); Zoledronic acid

Indexed keywords

ACTIN; ALPHA5 INTEGRIN; F ACTIN; FILAMIN A; UROKINASE RECEPTOR; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MESSENGER RNA;

ARTICLE; CANCER RESISTANCE; CELL CONTACT; CELL INTERACTION; CELL INVASION; CELL MEMBRANE; CELL MOTION; CELL NUCLEUS; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSKELETON; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; INVADOPODIA; LIQUID CHROMATOGRAPHY; MALE; PODOSOME; PROSTATE ADENOCARCINOMA; PROSTATE CANCER CELL LINE; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENETICS; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CELL MOVEMENT; CELL PROLIFERATION; DIPHOSPHONATES; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE ONTOLOGY; GENE REGULATORY NETWORKS; HUMANS; IMIDAZOLES; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED;

EID: 84925013613     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: Perspectives from autopsy studies. Can J Urol. 2008; 15:3866-3871.
2. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New agents for prostate cancer. Ann Oncol. 2014; 25:1700-1709.
3. Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM. Nuclear versus cytoplasmic localization of filamin a in prostate cancer: Immunohistochemical correlation with metastases. Clin Cancer Res. 2009; 15:788-796.
4. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011; 29:3705-3714.
5. Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, Budillon A, Venuta S, Abbruzzese A. The farnesyl transferase inhibitor r115777 (zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by zoledronic acid (zometa) and pamidronate. Oncogene. 2004; 23:6900-6913.
6. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol. 2006; 3:325-338.
7. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A. R115777 (zarnestra)/zoledronic acid (zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by erk/akt inactivation and reduced bcl-2 and bad phosphorylation. J Cell Physiol. 2007; 211:533-543.
8. Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-map kinase activation in prostate cancer cells. Cell Death Dis. 2013; 4:e641.
9. Popowicz GM, Schleicher M, Noegel AA, Holak TA. Filamins: Promiscuous organizers of the cytoskeleton. Trends Biochem Sci. 2006; 31:411-419.
10. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP. Urokinase receptor interacts with alpha (v)beta5 vitronectin receptor, promoting urokinase- dependent cell migration in breast cancer. Cancer Res. 1999; 59:5307-5314.
11. Almasi CE, Brasso K, Iversen P, Pappot H, Hoyer-Hansen G, Dano K, Christensen IJ. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate. 2011; 71:899-907.
12. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6:1-6.
13. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18:11-22.
14. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005; 7:1011-1019.
15. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008; 68:927-936.
16. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003; 63:3877-3882.
17. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001; 61:5692-5696.
18. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002; 1:203-209.
19. Zhu TN, He HJ, Kole S, D'Souza T, Agarwal R, Morin PJ, Bernier M. Filamin a-mediated down-regulation of the exchange factor ras-grf1 correlates with decreased matrix metalloproteinase-9 expression in human melanoma cells. J Biol Chem. 2007; 282:14816-14826.
20. Loy CJ, Sim KS, Yong EL. Filamin-a fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci U S A. 2003; 100:4562-4567.
21. Yue J, Lu H, Liu J, Berwick M, Shen Z. Filamin-a as a marker and target for DNA damage based cancer therapy. DNA Repair (Amst). 2011; 11:192-200.
22. Yamaguchi H, Takeo Y, Yoshida S, Kouchi Z, Nakamura Y, Fukami K. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res. 2009; 69:8594-8602.
23. Takkunen Minna a, Hukkanen Mika a, Liljeström Mikko a, Grenman Reidar b. Podosome-like structures of non-invasive carcinoma cells are replaced in epithelial-mesenchymal transition by actincomet-embedded invadopodia. J. Cell. Mol. Med. Vol 14, No 6B, 2010 pp. 1569-1593.
24. Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, Xu GJ, Song JD, Zhao FK. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer. 2007; 121:2596-2605.
25. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK. Prostate-specific membrane antigen association with filamin a modulates its internalization and naaladase activity. Cancer Res. 2003; 63:2645-2648.
26. Silvestri I, Longanesi Cattani I, Franco P, Pirozzi G, Botti G, Stoppelli MP, Carriero MV. Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha (v) beta5 vitronectin receptor cell surface expression. Int J Cancer. 2002; 102:562-71.
27. Thomas S, Chiriva-Internati M, Shah GV. Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling. Clin Exp Metastasis. 2007; 24:363-377.
28. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996; 85:683-93.
29. Lim LH, Pervaiz S. Annexin 1: The new face of an old molecule. FASEB J. 2007; 21:968-975.
30. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol. 2008; 216:131-140.
31. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. Expression of annexin a1 in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome. Clin Cancer Res. 2006; 12:4598-4604.
32. Liang L, Qu L, Ding Y. Protein and mrna characterization in human colorectal carcinoma cell lines with different metastatic potentials. Cancer Invest. 2007; 25:427-434.
33. Hayes MJ, Rescher U, Gerke V, Moss SE. Annexin-actin interactions. Traffic. 2004; 5:571-576.
34. Bizzarro V, Belvedere R, Dal Piaz F, Parente L, Petrella A. Annexin a1 induces skeletal muscle cell migration acting through formyl peptide receptors. PLoS One. 2012; 7:e48246.
35. Campos-Gonzalez R, Kanemitsu M, Boynton AL. Epidermal growth factor induces the accumulation of calpactin ii on the cell surface during membrane ruffling. Cell Motil Cytoskeleton. 1990; 15:34-40.
36. Perretti M, Getting SJ, Solito E, Murphy PM, Gao JL. Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol. 2001; 158:1969-1973.
37. Gavins FN, Yona S, Kamal AM, Flower RJ, Perretti M. Leukocyte antiadhesive actions of annexin 1: Alxr- and fpr-related anti-inflammatory mechanisms. Blood. 2003; 101:4140-4147.
38. Ernst S, Lange C, Wilbers A, Goebeler V, Gerke V, Rescher U. An annexin 1 n-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family. J Immunol. 2004; 172:7669-7676.
39. Katanaev VL. Signal transduction in neutrophil chemotaxis. Biochemistry (Mosc). 2001; 66:351-368.
40. Chodniewicz D, Zhelev DV. Novel pathways of f-actin polymerization in the human neutrophil. Blood. 2003; 102:2251-2258.
41. Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 2011; 17:1944-1961.
42. Cote MC, Lavoie JR, Houle F, Poirier A, Rousseau S, Huot J. Regulation of vascular endothelial growth factor-induced endothelial cell migration by lim kinase 1-mediated phosphorylation of annexin 1. J Biol Chem. 2010; 285:8013-8021.
43. Burke B, Stewart CL. The nuclear lamins: Flexibility in function. Nat Rev Mol Cell Biolb. 2012; 14:13-24.
44. Kong L, Schafer G, Bu H, Zhang Y, Klocker H. Lamin a/c protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the pi3k/akt/pten pathway. Carcinogenesis. 2012; 33:751-759.
45. Willis ND, Cox TR, Rahman-Casans SF, Smits K, Przyborski SA, van den Brandt P, van Engeland M, Weijenberg M, Wilson RG, de Bruine A, Hutchison CJ. Lamin a/c is a risk biomarker in colorectal cancer. PLoS One. 2008; 3:e2988.
46. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer. 2004; 4:349-360.
47. Corbi N, Batassa EM, Pisani C, Onori A, Di Certo MG, Strimpakos G, Fanciulli M, Mattei E, Passananti C. The eef1gamma subunit contacts rna polymerase ii and binds vimentin promoter region. PLoS One. 2011; 5:e14481.
48. Van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G. The aldehyde dehydrogenase enzyme 7a1 is functionally involved in prostate cancer bone metastasis. Clin Exp Metastasis. 2011; 28:615-625.
49. Reinstein E, Frentz S, Morgan T, García-Miñaúr S, Leventer RJ, McGillivray G, Pariani M, van der Steen A, Pope M, Holder-Espinasse M, Scott R, Thompson EM, Robertson T, Coppin B, Siegel R, Bret Zurita M, Rodríguez JI, Morales C, Rodrigues Y, Arcas J, Saggar A, Horton M, Zackai E, Graham JM, Rimoin DL, Robertson SP. Vascular and connective tissue anomalies associated with X-linked periventricular heterotopia due to mutations in Filamin A. Eur J Hum Genet. 2013 May; 21:494-502. doi:10.1038/ejhg.2012.209. Epub 2012 Oct 3.
50. Yang YH, Morand E, Leech M, Annexin A. potential for glucocorticoid sparing in RA. Nat Rev Rheumatol. 2013 Oct; 9:595-603.
51. Rocha-Perugini Vera, González-GranadoJosé M. Nuclear envelope lamin-A as a coordinator of T cell activation. Nucleus 5:5, 396-401; September/October 2014; © 2014 Landes Bioscience.
52. Camozzi D, Capanni C, Cenni V, Mattioli E, Columbaro M, Squarzoni S, Lattanzi G. Diverse lamin-dependent mechanisms interact to control chromatin dynamics: Focus on laminopathies. Nucleus. 2014 Sep 2.
53. Bianchi L, Bruzzese F, Leone A, Gagliardi A, Puglia M, Di Gennaro E, Rocco M, Gimigliano A, Pucci B, Armini A, Bini L, Budillon A. Proteomic analysis identifies differentially expressed proteins after hdac vorinostat and egfr inhibitor gefitinib treatments in hep-2 cancer cells. Proteomics. 2011; 11:3725-3742.
54. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-254.